Bold claim: a groundbreaking experimental RNA drug could repair DNA and repair tissue damage, offering a new class of medicines beyond traditional stem cell therapies.
Cedars-Sinai researchers have introduced TY1, an experimental drug that targets tissue damage from heart attacks, inflammatory diseases, and related conditions. The team describes how TY1 works in Science Translational Medicine, presenting it as a prototype for therapies that heal without stem cells.
TY1 is a lab-made RNA molecule modeled after a natural transcript in the body. It boosts the activity of the TREX1 gene, which helps immune cells clear damaged DNA. By accelerating this cleanup, TY1 promotes tissue repair.
The journey to TY1 spans more than two decades. It began with a Johns Hopkins technique to isolate heart progenitor cells—cells that can evolve into healthy heart tissue but with a pinpointed, focused regenerative ability compared with broad stem cell approaches. At Cedars-Sinai, Ahmed Ibrahim, PhD, MPH, later found that these heart progenitor cells release exosomes—tiny sacs packed with RNA molecules that aid repair and regeneration.
To uncover which messages within exosomes mattered most, scientists sequenced the RNA inside them. They identified a particular RNA molecule that appeared especially abundant and potentially involved in healing. In laboratory animals, the natural RNA molecule aided recovery after heart injury. TY1 is the engineered version designed to mimic that RNA’s structure and function, aligning with approved RNA medicines already in clinical use. It works by increasing immune-driven DNA repair, which helps limit scar formation after a heart attack.
Ibrahim emphasizes the broader potential: enhancing DNA repair with TY1 could address tissue damage not only from heart events but also from autoimmune diseases where the body attacks healthy tissue. This represents a novel mechanism for healing, with implications across multiple disorders.
Next steps involve moving TY1 into clinical trials to evaluate safety and efficacy in humans.
Source: Journal reference:
